智慧生物学系
黄渊余 教授 / 博士生导师
1、个人信息
姓名：黄渊余；学位：理学博士；职称：教授（博士生导师）
入选了国家级青年人才、北京市科技新星、北京市科协青年托举人才，入选斯坦福大学发布的全球前2%顶尖科学家榜单（2020-2023连续四年）
2、联系方式：
地址：北京市海淀区中关村南大街5号北京理工大学前沿交叉科学研究院、生命学院
电话：010-68911089
E-mail：yyhuang@bit.edu.cn
3、个人简历
2016.07至今 北京理工大学前沿交叉科学研究院/生命学院，助理教授（副研究员）、长聘副教授（研究员）、长聘教授，院长助理，核酸诊疗与精准医学团队负责人，博士生导师
2013.06-2016.06 在北京大学分子医学研究所开展博士后研究
2008.09-2013.06 在北京大学学习并获得理学博士学位
2004.09-2008.07 在中南大学学习并获得理学学士学位
4、学术任职
期刊任职：
2021至今，Exploration (ESCI, Wiley综合期刊，IF≈20) ，创刊副主编
2024至今，Trends in Molecular Medicine (SCI，中科院1区)，顾问编委
2018至今，Chinese Chemical Letters (SCI，中科院1区)，青年编委
2021至今，生物化学与生物物理进展 (SCI)，编委
2019至今，Nano Biomedicine and Engineering，编委
2019至今，生命科学仪器，编委
学术组织任职：
2019至今 中国生物物理学会纳米生物学分会，秘书长、委员
2023至今 中国疫苗行业协会疫苗基础研究专委会，委员
2022至今 中国生物材料学会智能仿生生物材料分会、青年工作委员会，委员
2021至今 中国抗癌协会纳米肿瘤分会 委员
2019至今 中国医药生物技术协会造影技术分会、基因编辑分会、生物制药技术分会，理事
2019至今 中国生物医学工程学会纳米医学与工程分会，委员
2019至今 北京市理化分析测试技术学会核酸适配体交叉技术分会，理事
5、研究领域和方向
研究领域：核酸药物与疫苗，具体包括：
− 核酸药物（如siRNA等）的设计筛选、化学修饰、药物递送及其药物研究；
− 基于mRNA的疫苗与药物研究；
− 基于核酸适配体、CRISPR/Cas等核酸分子的疾病诊疗新技术。
覆盖的疾病类型包括：恶性肿瘤、代谢疾病、感染性疾病、神经疾病、眼科疾病等。
6、研究技术与手段：
本课题组的研究立足于生物学和生物医学工程，专业内容涉及药学、制药工程、高分子材料、化学与化工、基础医学等多个学科，从分子到细胞、再到疾病动物模型开展多层次研究，常用实验手段包括分子克隆、实时定量PCR、Western Blot，细胞培养、核酸转染，疾病模型构建，动物给药、取样，小动物活体成像，病理/冰冻切片制作与观察等。
7、招生专业
学术型硕士生专业：生物学
专业型硕士生专业：生物技术与工程
学术博士生专业：生物学
工程博士生专业：生物与医药
第二招生学科：材料科学与工程
8、科研项目（不完全列举）
⒈ 抗高尿酸血症核酸药物研发，中关村科技园区大兴生物医药产业基地核酸药物“揭榜挂帅”技术攻关项目，2022.11-2025.10，主持人
⒉ 新型mRNA疫苗平台体系研究，科技部重点研发 “病原学与防疫技术体系研究” 专项“揭榜挂帅”项目，2021YFC2302402，2022.01-2026.12，课题负责人
⒊ 基于双亲性可离子化高分子组装体的抗病毒纳米药物研究，科技部重点研发“纳米前沿” 专项，2021YFA1201002，2021.12-2026.12，子课题负责人
⒋ 调控自噬的载药NK外泌体对慢性淋巴细胞白血病的化疗与免疫治疗增敏，国家自然科学基金面上项目，32171394，2022.01-2025.12，主持人
⒌ 分级响应的PD-L1抗体/siRNA外泌体组合物介导肿瘤多机制联合治疗，国家自然科学基金面上项目，31871003，2019.01-2022.12，主持人
⒍ 自组装多肽递送siRNA重塑肿瘤微环境的精准纳米基因治疗，北京市科技新星交叉合作项目，20220884207，2022.11-2024.10，主持人
⒎ 核酸工程化NK外泌体协同治疗急性髓系白血病，北京市科技新星计划， Z201100006820005，2020.09-2022.08，主持人
9、学术成果：
研究兴趣主要围绕核酸药物与疫苗展开。截至2024年02月，以通讯/第一作者在Nat Rev Bioeng、Sci Adv、Signal Transduct Target Ther、Adv Mater、Trends Mol Med、Nano Lett、Adv Funct Mater、Adv Sci等发表论文70余篇，IF>10论文约40篇，ESI高被引论文10篇，热点论文2篇；共发表论文110余篇，撰写10余部专著章节，申请专利约40件，含PCT专利10余件。
作为课题或项目负责人主持承担国家重点研发计划、国家自然科学基金等项目10余项；获得北京市科学技术奖自然科学一等奖（排名第九）、广西科学技术奖自然科学一等奖（排名第五），中美纳米医学与纳米生物技术学会“Rising Star”奖，Journal of Materials Chemistry B期刊的Emerging Investigator等荣誉。
9.1 已发表论文：
（1）第一或通讯作者论文（#: 第一作者, *: 通讯作者；不含署名作者论文；按时间排序）
1. Guo S#, Tang D, Zhang M, Yang H, Zhang T, Hu B, Xu C, Weng Y, Shang K*, Huang Y*. Spatiotemporal-controlled NIR-II Immune Agonist Sensitizes Cancer Immunotherapy. Adv Mater. 2024 Mar 13:e2400228. (IF= 29.4, 中科院1区)
2. Xiao Y#, Huang Y#,*, Xie M#, Yang M, Tao Y, Liu L, Wu J, Xie G, Liu J, Xu T, Guo W*, Liang X-J*. Immunoregulatory nanomedicine for respiratory infections. Nat Rev Bioeng. 2024;2:244–259.
3. Jiang S, Li W, Yang J, Zhang T, Zhang Y, Xu L, Hu B, Li Z, Gao H*, Huang Y*, Ruan S*. Cathepsin B-Responsive Programmed Brain Targeted Delivery System for Chemo-Immunotherapy Combination Therapy of Glioblastoma. ACS Nano. 2024 Feb 27;18(8):6445-6462. (IF= 17.1, 中科院1区)
4. Yang M#, Li C#, Ye G#, Shen C#, Shi H, Zhong L, Tian Y, Zhao M, Wu P, Hussain A, Zhang T, Yang H, Yang J, Weng Y, Liu X, Wang Z, Gan L, Zhang Q, Liu Y, Yang G*, Huang Y*, Zhao Y*. Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibited potential anti pan-coronavirus activity. Signal Transduct Target Ther. 2024 Feb 14;9(1):40. (IF= 39.3, 中科院1区)
5. Moazzam M, Zhang M, Hussain A, Yu X*, Huang J*, Huang Y*. The Landscape of Nanoparticle-based siRNA Delivery and Therapeutic Development. Mol Ther. 2024 Feb 7;32(2):284-312. (IF= 12.4, 中科院1区)
6. Essola JM#, Zhang M#, Yang H, Li F, Xia B, Mavoungou JF, Hussain A*, Huang Y*. Exosome regulation of immune response mechanism: Pros and cons in immunotherapy. Bioact Mater. 2023 Oct 4;32:124-146. (IF= 18.9, 中科院1区)
7. Guo S, Zhang M, Huang Y*. Three 'E' challenges for siRNA drug development. Trends Mol Med. 2024 Jan;30(1):13-24. (IF=13.6, 中科院1区)
8. Tian Y#, Li M#, Yang Y#, Li C, Peng Y, Yang H, Zhao M, Wu P, Ruan S, Huang Y*, Shen C*, Yang M*. An MPXV mRNA-LNP vaccine candidate elicits protective immune responses against monkeypox virus. Chin Chem Lett. 2023 https://doi.org/10.1016/j.cclet.2023.109270 (IF= 9.1, 中科院1区)
9. Zheng L#, Hu B#, Zhao D, Liu W, Liu Q, Huang Y*, Ruan S*. Recent progresses of exosome–liposome fusions in drug delivery. Chin Chem Lett. 2024 Feb; 35(2): 108647 (IF= 9.1, 中科院1区)
10. Hu B#, Kong S#, Weng Y, Zhao D, Hussain A, Jiao Q, Zhan S, Qiu L, Lin J, Xie M*, Li B*, Huang Y*. Lipid-conjugated siRNA hitchhikes endogenous albumin for tumor immunotherapy. Chin Chem Lett. 2023 Nov; 34(11): 108210 (IF= 9.1, 中科院1区)
11. Lu M#, Xing H#, Shao W, Wu P, Fan Y, He H, Barth S, Zheng A, Liang X-J*, Huang Y*. Antitumor synergism between PAK4 silencing and immunogenic phototherapy of engineered extracellular vesicles. Acta Pharm Sin B. 2023 Sep.; 13(9): 3945-3955. (IF= 14.5, 中科院1区)
12. Cong W, Wang Y, Yuan C, Xu M, Wang H, Hu Y, Dai X, Weng Y, Timashev P, Liang XJ, Huang Y*. Dietary cobalt oxide nanoparticles alleviate aging through activation of mitochondrial UPR in Caenorhabditis elegans. Theranostics. 2023 May 27;13(10):3276-3289. (IF= 12.4, 中科院1区)
13. Zhang X, Yang G*, Liu W, Liu Q, Wang Z, Fan K, Qu F, Huang Y*. Screening and Identification of ssDNA Aptamers for Low-Density Lipoprotein (LDL) Receptor-Related Protein 6. Molecules. 2023 Apr 30;28(9):3838. (IF= 4.6, 中科院2区)
14. Hu B, Huang Y*. siRNA targeting ANGPTL3 stands in the spotlight for lipid-lowering therapy. Mol Ther Nucleic Acids. 2023 Apr 19;32:369-370. (IF= 8.8, 中科院1区)
15. Zhang X, Yang G*, Zhao Y, Dai X, Liu W, Qu F, Huang Y*. Selection and Identification of an ssDNA Aptamer for Fibroblast Activation Protein. Molecules. 2023 Feb 9;28(4):1682. (IF= 4.6, 中科院2区)
16. Lu M#*, Shao W#, Xing H, Huang Y*. Extracellular vesicle-based nucleic acid delivery. Interdiscip Med. 2023, n/a (n/a), e20220007. (Wiley新期刊)
17. Lu M#, Xing H#, Zheng A, Huang Y*, Liang XJ*. Overcoming Pharmaceutical Bottlenecks for Nucleic Acid Drug Development. Acc Chem Res. 2023 Feb 7;56(3):224-236. (IF= 18.3, 中科院1区)
18. Cong W, Meng L, Pan Y, Wang H, Zhu J, Huang Y*, Huang Q*. Mitochondrial-mimicking nanozyme-catalyzed cascade reactions for aging attenuation. Nano Today 2023 Feb; 48: 101757. (IF= 17.4, 中科院1区)
19. Zhang M, Hussain A*, Yang H, Zhang J, Liang X-J, Huang Y*. mRNA-based modalities for infectious disease management. Nano Res. 2023; 16(1): 672-691. (IF= 9.9, 中科院1区)
20. Liu R#, Luo C#, Pang Z#, Zhang J#, Ruan S#, Wu M#, Wang L#, Sun T#, Li N#, Han L#, Shi J#, Huang Y#, Guo W#, Peng S#, Zhou W#, Gao H*. Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. Chin Chem Lett. 2023; 34(2):107518. (ESI 1%, hot paper) (IF= 9.1, 中科院1区)
21. Zhang M, Huang Y*. siRNA modification and delivery for drug development. Trends Mol Med. 2022 Oct;28(10):892-893. (IF=13.6, 中科院1区)
22. Zhang T#, Guo S#, Li F*, Lan X, Jia Y, Zhang J, Huang Y*, Liang X-J*. Imaging-guided/improved diseases management for immune-strategies and beyond. Adv Drug Deliv Rev. 2022 Sep;188:114446. (IF= 16.1, 中科院1区)
23. Lu M#, Xing H#, Shao W, Zhang T, Zhang M, Wang Y, Li F, Weng Y, Zheng A, Huang Y*, Liang X-J*. Photo-activatable Silencing Extracellular Vesicle (PASEV) Sensitizes Cancer Immunotherapy. Adv Mater. 2022 Sep;34(35):e2204765. (IF= 29.4, 中科院1区)
24. Yu C#, Li K#, Xu L, Li B, Li C, Guo S, Li Z, Zhang Y, Hussain A, Tan H, Zhang M, Zhao Y*, Huang Y*, Liang X-J*. siRNA-Functionalized Lanthanide Nanoparticle Enables Efficient Endosomal Escape and Cancer Treatment. Nano Res. 2022, 15(10): 9160-9168. (IF= 9.9, 中科院1区)
25. Zhang M, Shao W, Yang T, Liu H, Guo S, Zhao D, Weng Y, Liang X-J, Huang Y*. Conscription of Immune Cells by Light-Activatable Silencing NK-Derived Exosome (LASNEO) for Synergetic Tumor Eradication. Adv Sci (Weinh). 2022 Aug;9(22):e2201135. (IF= 15.1, 中科院1区)
26. Liu W, Huang Y*. Cell membrane-engineered nanoparticles for cancer therapy. J. Mater. Chem. B. 2022 Sep 28;10(37):7161-7172. (IF= 7.0, 中科院2区)
27. Hussain A, Yang H, Zhang M, Liu Q*, Alotaibi G, Irfan M, He H, Chang J, Liang XJ, Weng Y, Huang Y*. mRNA vaccines for COVID-19 and diverse diseases. J Control Release. 2022 Mar 21;345:314-333. (ESI 1%) (IF= 10.8, 中科院1区)
28. Zhang Y#, Li Z#, Milon Essola J, Ge K, Dai X, He H, Xiao H, Weng Y*, Huang Y*. Biosafety materials: ushering in a new era of infectious disease diagnosis and treatment with the CRISPR/Cas system. Biosaf Health. 2022 Apr;4(2):70-78. (国产生物安全领域英文期刊，ESCI)
29. Liu W#, Huang Y#, Li Z, Li L, Zhao Y, Li M*. Multivalent Engineering of Exosomes with Activatable Aptamer Probes for Specific Regulation and Monitoring of Cell Targeting. Anal Chem. 2022 Mar 8;94(9):3840-3848. (IF=7.4, 中科院1区)
30. Hu B, Li B, Li K, Liu Y, Li C, Zheng L, Zhang M, Yang T, Guo S, Dong X, Zhang T, Liu Q, Hussain A, Weng Y, Peng L, Zhao Y, Liang XJ, Huang Y*. Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia. Sci Adv. 2022 Feb 18;8(7):eabm1418. (ESI 1%) (IF= 13.6, 中科院1区)
31. Huang Y*, Zheng S, Guo Z, de Mollerat du Jeu X, Liang XJ, Yang Z, Zhang HY, Gao S, Liang Z*. Ionizable liposomal siRNA therapeutics enables potent and persistent treatment of Hepatitis B. Signal Transduct Target Ther. 2022 Feb 11;7(1):38. (IF= 39.3, 中科院1区)
32. Li C#, Yang T#, Weng Y#, Zhang M, Zhao D, Guo S, Hu B, Shao W, Wang X, Hussain A, Liang X, Huang Y*. Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy. Bioact Mater. 2022 Jun 25;9:590-601. (ESI 1%) (IF= 18.9, 中科院1区)
33. Liu Q, Wu B, Li M*, Huang Y*, Li L*. Heterostructures Made of Upconversion Nanoparticles and Metal-Organic Frameworks for Biomedical Applications. Adv Sci. 2022 Jan;9(3):e2103911. (IF= 15.1, 中科院1区)
34. Guo S, Li K, Hu B, Li C, Zhang M, Hussain A, Wang X, Cheng Q, Yang F, Ge K, Zhang J, Chang J, Liang X-J, Weng Y, Huang Y*. Membrane-destabilizing ionizable lipid empowered imaging-guided siRNA delivery and cancer treatment. Exploration. 2021, 1(1): 35-49. (Wiley新期刊，即时IF>18)
35. Li K, Zhang Y, Hussain A*, Weng Y*, Huang Y*. Progress of Photodynamic and RNAi Combination Therapy in Cancer Treatment. ACS Biomater Sci Eng. 2021, 7(9): 4420–4429. (IF= 5.8, 中科院2区)
36. 杨海银,张萌洁,翁郁华,曹毅,黄渊余*. COVID-19核酸疫苗及其纳米递送系统. 中国科学: 生命科学, 2021. 7: 804-818. Yang H, Zhang M, Weng Y, Cao Y, Huang Y*. Nucleic acid-based vaccines of COVID-19 and their delivery systems. SCIENTIA SINICA Vitae. 2021. 7: 804-818. (中文核心期刊)
37. Yang G, Li Z, Mohammed I, Zhao L, Wei W, Xiao H, Guo W, Zhao Y, Qu F, Huang Y*. Identification of SARS-CoV-2-against aptamer with high neutralization activity by blocking the RBD domain of spike protein 1. Signal Transduct Target Ther. 2021 Jun 10;6(1):227. (IF= 39.3, 中科院1区)
38. Weng Y, Huang Y*. Advances of mRNA vaccines for COVID-19: a new prophylactic revolution begins. Asian J Pharm Sci. 2021. 16(3): 263-264. (IF= 10.2, 中科院1区)
39. 李子玥,杨同仁,杨歌,黄渊余*. 病原微生物的核酸检测分析研究进展. 应用化学. 2021. 38(5):592-604. Li Z. Yang T. Yang G. Huang Y*. Research Progresses of Nucleic Acid Based Detection of Pathogenic Microorganisms. Chinese Journal of Applied Chemistry. 2021. 38(5):592-604.
40. Li C, Zhou J, Wu Y, Dong Y, Du L, Yang T, Wang Y, Guo S, Zhang M, Hussain A, Xiao H, Weng Y, Huang Y, Wang X, Liang Z, Cao H, Zhao Y, Liang X, Dong A, Huang Y*. Core Role of Hydrophobic Core of Polymeric Nanomicelle in Endosomal Escape of siRNA. Nano Lett. 2021 Feb 17. 21(8): 3680–3689. (IF= 10.8, 中科院1区)
41. Yang T#, Huang D#, Li C, Zhao D, Li J, Zhang M, Chen Y, Wang Q, Liang Z, Liang X, Li Z*, Huang Y*. Rolling microneedle electrode array (RoMEA) empowered nucleic acid delivery and cancer immunotherapy. Nano Today. 2021 Nov 2. 36：10101. (IF= 17.4, 中科院1区)
42. Guo S, Liu B, Zhang M, Li C, Wang X, Weng Y, Li L, Huang Y*. A novel polyethyleneimine-decorated FeOOH nanoparticle for efficient siRNA delivery. Chin Chem Lett. 2021 Nov 20. 32(1): 102-106. (IF= 9.1, 中科院1区)
43. Yang T#, Li C#, Wang X#, Zhao D, Zhang M, Cao H, Liang Z, Xiao H, Liang X, Weng Y*, Huang Y*. Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle. Bioact Mater. 2020, 5 (4): 1053-1061. (IF=18.9, 中科院1区)
44. Wang S, Ma J, Guo S, Huang Y*, Cao Y*. Transcriptomic analysis revealed that multi-walled carbon nanotubes diameter-dependently induced pyroptosis in THP-1 macrophages. NanoImpact. 2020, 20: 100270. (IF= 4.9, 中科院3区)
45. Yu C, Xu L, Zhang Y, P Timashev P, Huang Y*, Liang X-J*. Polymer-Based Nanomaterials for Noninvasive Cancer Photothermal Therapy. ACS Appl Polym Mater. 2020, 2(10): 4289–4305. (IF= 5.0, 中科院2区)
46. Yang T, Yu C, Wang C, Li C, Zhang M, Luo X, Weng Y, Dong A, Li X, Deng Y, Huang Y*. The microgravity enhanced polymer-mediated siRNA gene silence by improving cellular uptake. Biophysics Reports. 2020. 6(6): 266-277. (中国生物物理学会期刊)
47. Li K, Lu M*, Xia X-H, Huang Y*. Recent advances in photothermal and RNA interfering synergistic therapy. Chin Chem Lett. 2020,32(3):1010-1016. (IF= 9.1, 中科院1区)
48. Yin D, Zhang M, Chen J, Huang Y*, Liang D*. Shear-responsive peptide/siRNA complexes as lung-targeting gene vectors. Chin Chem Lett. 2020 Dec 11. 32(5): 1731-1736. (IF= 9.1, 中科院1区)
49. Liu H, Huang L, Mao M, Ding J, Wu G, Fan W, Yang T, Zhang M, Huang Y*, Xie H-Y*. Viral Protein‐Pseudotyped and siRNA‐Electroporated Extracellular Vesicles for Cancer Immunotherapy. Adv Funct Mater. 2020: 2006515. (IF= 19.0, 中科院1区)
50. 张玉权,郭帅,翁郁华,杨勇飞,黄渊余*. 聚集诱导发光材料在药物递送与疾病治疗中的研究进展. 化工学报. 2020 Jun 30. 71(9): 4102-4111. Zhang Y, Guo S, Weng Y, Yang Y, Huang Y*. Progresses of aggregation-induced emission materials in drug delivery and disease treatment. CIESC Journal. 2020 Jun.30. 71(9): 4102-4111.
51. 张玉权, 黄渊余*. 聚集诱导发光荧光探针在生物成像中的研究进展. 生命科学仪器 2020; 18(8): 03-11. Zhang Y. Huang Y*. Progresses of Aggregation-Induced Emission Fluorescent Probes in Bioimaging. Life Science Instruments. 2020; 18(8): 03-11.
52. Zhang M, Weng Y, Cao Z, Guo S, Hu B, Lu M, Guo W, Yang T, Li C, Yang X, Huang Y*. ROS-Activatable siRNA-Engineered Polyplex for NIR-Triggered Synergistic Cancer Treatment. ACS Appl Mater Interfaces. 2020 Jul 22;12(29):32289-32300. (IF= 9.5, 中科院2区，Top期刊)
53. Hu B#, Zhong L#, Weng Y, Peng L, Huang Y*, Zhao Y*, Liang XJ*. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020 Jun 19;5(1):101. (ESI 1%) (IF= 39.3, 中科院1区)
54. 赵子璇#,李春辉#,周莉莉,赵德尧,翁郁华,夏新华,黄渊余*. CRISPR/Cas系统递送技术及其应用研究进展. 生物化学与生物物理进展. 2020. 47(4): 286-299. Zhao Z #, Li C #, Zhou L, Zhao D, Weng Y, Xia X, Huang Y. Delivery and Application Progresses of CRISPR/Cas Gene Editing System. Prog Biochem Biophys. 2020. 47(4): 286-299. (IF= 0.3, 中科院4区)
55. Lu M, Huang Y*. Bioinspired exosome-like therapeutics and delivery nanoplatforms. Biomaterials. 2020 Mar 2;242: 119925. (ESI 1%) (IF= 14.0, 中科院1区)
56. Zhao D#, Yang G#, Liu Q, Liu W, Weng Y, Zhao Y, Qu F, Li L, Huang Y*. A photo-triggerable aptamer nanoswitch for spatiotemporal controllable siRNA delivery. Nanoscale. 2020 May 28;12(20):10939-10943. (IF= 6.7, 中科院2区)
57. Weng Y, Li C, Yang T, Hu B, Zhang M, Guo S, Xiao H, Liang XJ, Huang Y*. The challenge and prospect of mRNA therapeutics landscape. Biotechnol Adv. 2020 May-Jun;40:107534. (ESI 1%) (IF= 16.0, 中科院1区)
58. Weng Y, # Huang Q#, Li C, Yang Y, Wang X, Yu J, Huang Y*, Liang XJ*. Improved Nucleic Acid Therapy with Advanced Nanoscale Biotechnology. Mol Ther Nucleic Acids. 2020 Mar 6;19:581-601. (IF= 8.8, 中科院1区)
59. Hu B#, Weng Y#, Xia XH, Liang XJ, Huang Y*. Clinical advances of siRNA therapeutics. J Gene Med. 2019 Jul;21(7):e3097. (IF= 3.5, 中科院3区)
60. 李春辉, 胡泊, 翁郁华, 黄渊余*. 基因治疗的现状与临床研究进展. 生命科学仪器. 2019 Aug; 17: 3-12. Li C, Hu B, Weng Y, Huang Y*. Current Situation and Clinical Research Progresses of Gene Therapy. Life Science Instruments. 2019 Aug. 17(4): 3-12.
61. Weng Y, Xiao H, Zhang J, Liang XJ, Huang Y*. RNAi therapeutic and its innovative biotechnological evolution. Biotechnol Adv. 2019 Sep - Oct;37(5):801-825. (ESI 1%) (IF= 16.0, 中科院1区)
62. 黄渊余*. 首例RNA干扰药物问世及该领域技术演化历程.生物化学与生物物理进展. 2019 Mar.; 46(3):313-322. Huang Y*. Approval of The First-Ever RNAi Therapeutics and Its Technological Development History. Prog Biochem Biophys. 2019 Mar.; 46(3):313-322. (IF= 0.3, 中科院4区)
63. Huang D#, Zhao D#, Li J, Wu Y, Du L, Xia XH, Li X, Deng Y, Li Z, Huang Y*. Continuous Vector-free Gene Transfer with a Novel Microfluidic Chip and Nanoneedle Array. Curr Drug Deliv. 2019;16(2):164-170. (IF= 2.4, 中科院4区)
64. Zhang T#, Huang Y#, Ma X#, Gong N, Liu X, Liu L, Ye X, Hu B, Li C, Tian JH, Magrini A, Zhang J, Guo W*, Xing JF*, Bottini M, Liang XJ*. Fluorinated Oligoethylenimine Nanoassemblies for Efficient siRNA-Mediated Gene Silencing in Serum-Containing Media by Effective Endosomal Escape. Nano Lett. 2018 Oct 10;18(10):6301-6311. (IF= 10.8, 中科院1区)
65. Zheng S#, Wang X#, Weng YH#, Jin X, Ji JL, Guo L, Hu B, Liu N, Cheng Q, Zhang J, Bai H, Yang T, Xia XH, Zhang HY, Gao S, Huang Y*. siRNA Knockdown of RRM2 Effectively Suppressed Pancreatic Tumor Growth Alone or Synergistically with Doxorubicin. Mol Ther Nucleic Acids. 2018 Sep 7;12:805-816. (IF= 8.8, 中科院1区)
66. Huang D#, Zhao D#, Wang X, Li C, Yang T, Du L, Wei Z, Cheng Q, Cao H, Liang Z, Huang Y*, Li Z*. Efficient delivery of nucleic acid molecules into skin by combined use of microneedle roller and flexible interdigitated electroporation array. Theranostics. 2018 Mar 22;8(9):2361-2376. (IF= 12.4, 中科院1区)
67. Huang Y*. Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics. Mol Ther Nucleic Acids. 2017 Mar 17;6:116-132. (ESI 1%, hot paper) (IF= 8.8, 中科院1区)
68. Zhou J#, Wu Y#, Wang C, Cheng Q, Han S, Wang X, Zhang J, Deng L, Zhao D, Du L, Cao H, Liang Z, Huang Y*, Dong A*. pH-Sensitive Nanomicelles for High-Efficiency siRNA Delivery in Vitro and in Vivo: An Insight into the Design of Polycations with Robust Cytosolic Release. Nano Lett. 2016 Nov 9;16(11):6916-6923. (IF= 10.8, 中科院1区)
69. Huang Y*, Cheng Q, Ji JL, Zheng S, Du L, Meng L, Wu Y, Zhao D, Wang X, Lai L, Cao H, Xiao K, Gao S, Liang Z*. Pharmacokinetic behaviors of intravenously administered siRNA in glandular tissues. Theranostics. 2016 Jun 18; 6(10): 1528-1541. (IF= 12.4, 中科院1区)
70. Huang Y*, Cheng Q, Jin, X, Ji JL, Guo S, Zheng S, Wang X, Cao H, Gao S, Liang XJ, Du Q*, Liang Z*. Systemic and Tumor-targeted Delivery of siRNA by Cyclic NGR and isoDGR Motif-containing Peptide. Biomater Sci. 2016 Feb 23;4(3):494-510. (IF= 6.6, 中科院3区)
71. Huang Y*, Wang X, Huang W, Cheng Q, Zheng S, Guo S, Cao H, Liang XJ, Du Q*, Liang Z*. Systemic Administration of siRNA via cRGD-containing Peptide. Sci Rep. 2015 Aug 24;5:12458. (IF= 4.6, 中科院2区)
72. 黄渊余*,梁子才*. 去唾液酸糖蛋白受体及其在药物肝靶向递送中的应用. 生物化学与生物物理进展. 2015 Jun; 42(6): 501-10. Huang Y*, Liang Z*. Asialoglycoprotein Receptor and Its Application in Liver-targeted Drug Delivery. Prog Biochem Biophys. 2015 Jun; 42(6): 501-10. (IF= 0.3, 中科院4区)
73. Wei Z#, Huang Y#, Zhao D, Hu Z*, Li Z*, Liang Z*. A pliable electroporation patch (ep-Patch) for efficient delivery of nucleic acid molecules into animal tissues with irregular surface shapes. Sci Rep. 2015 Jan 5;5:7618. (IF= 4.6, 中科院2区)
74. Cheng Q#, Huang Y#,*, Zheng H, Wei T, Zheng S, Huo S, Wang X, Du Q, Zhang X, Zhang HY, Liang XJ, Wang C, Tang R*, Liang Z*. The effect of guanidinylation of PEGylated poly(2-aminoethyl methacrylate) on the systemic delivery of siRNA. Biomaterials. 2013 Apr;34(12):3120-31. (IF= 14.0, 中科院1区)
75. Huang Y#, Lin D#, Jiang Q, Zhang W, Guo S, Xiao P, Zheng S, Wang X, Chen H, Zhang HY, Deng L, Xing J, Du Q, Dong A*, Liang Z*. Binary and ternary complexes based on polycaprolactone-graft-poly (N, N-dimethylaminoethyl methacrylate) for targeted siRNA delivery. Biomaterials. 2012 Jun;33(18):4653-64. (IF= 14.0, 中科院1区)
76. Lin D#, Huang Y#, Jiang Q, Zhang W, Yue X, Guo S, Xiao P, Du Q, Xing J, Deng L, Liang Z*, Dong A*. Structural contributions of blocked or grafted poly(2-dimethylaminoethyl methacrylate) on PEGylated polycaprolactone nanoparticles in siRNA delivery. Biomaterials. 2011 Nov;32(33):8730-42. (IF= 14.0, 中科院1区)
77. Guo S#, Huang Y#, Zhang W, Wang W, Wei T, Lin D, Xing J, Deng L, Du Q, Liang Z*, Liang XJ*, Dong A*. Ternary complexes of amphiphilic polycaprolactone-graft-poly (N,N-dimethylaminoethyl methacrylate), DNA and polyglutamic acid-graft-poly(ethylene glycol) for gene delivery. Biomaterials. 2011 Jun;32(18):4283-92. (IF= 14.0, 中科院1区)
78. Huang Y, Hong J, Zheng S, Ding Y, Guo S, Zhang H, Zhang X, Du Q*, Liang Z*. Elimination pathways of systemically delivered siRNA. Mol Ther. 2011 Feb;19(2):381-5. (IF= 12.4, 中科院1区)
79. Guo S#, Huang Y#, Jiang Q, Sun Y, Deng L, Liang Z, Du Q, Xing J, Zhao Y, Wang PC, Dong A, Liang XJ*. Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte. ACS Nano. 2010 Sep 28. 4(9):5505-11. (ESI 1%) (IF= 17.1, 中科院1区)
9.2 专著和书籍：
1. Yang G, Liu W, Huang Y*. Chapter 2 - Aptamer and its selection via various SELEX strategies. In book: Aptamers for Food Applications - Safety, Authenticity, and Integrity. In: Yiyang Dong, (eds.), May 27, 2023. ISNB: 978-0-323-91903-6. https://shop.elsevier.com/books/aptamers-for-food-applications/dong/978-0-323-91903-6
2. Hu B, Hussain A, Liu Q, Weng Y, Huang Y*. Chapter 13 - Advances in mRNA Delivery and Clinical Applications. In book: Messenger RNA Therapeutics. In: Stefan Jurga, Jan Barciszewski (eds.), September 2022. ISBN: 978-3-031-08414-0. DOI: 10.1007/978-3-031-08415-7_13
3. Lu M, Xing H, Huang Y*. Chapter 41 - Harnessing Exosomes and Bioinspired Exosome-Like Nanoparticles for siRNA Delivery. In: Peixuan Guo, Kirill A. Afonin (eds.), RNA Nanotechnology and Therapeutics. July 2022. ISBN: 978-1-4939-2562-9. DOI: 10.1201/9781003001560-45
4. Li C, Weng Y, Dong A, Liang X-J*, Huang Y*. Chapter 9 - Preparation and Evaluation of Rationally Designed Polymers for Efficient Endosomal Escape of siRNA. In: H. Tian and X. Chen (eds.), Gene Delivery, Biomaterial Engineering. 2021: 181-197. https://doi.org/10.1007/978-981-33-6198-0_4-1
5. Hussain A, Weng Y, Huang Y*. Chapter 9 - Graphene and graphene-based nanomaterials current applications and future perspectives. In: Shahzad, Rizvi, Yousaf, and Hussain. (eds) Drug Delivery using Nanomaterials. 2021, 209-228.
6. Dong Z#, Yang T#, Wu H, Brooks J. Yang R*, Huang Y*, Chang L*. Chapter 5 - Advanced microfluidic devices for cell electroporation and manipulation. In: Liu X, Sun Y. (eds) Micro and Nano Systems for Biophysical Studies of Cells and Small Organisms. 2021, 105-123.
7. Yang G, Huang Y*. Aptamers for Targeted Therapy. In: Dong Y. (eds) Chapter 6 - Aptamers for Medical Applications. Springer, Singapore. 2021, 129-178.
8. Lu M#, Zhang M#, Hu Bo, Huang Y*. Chapter 6 - siRNA Design and GalNAc-Empowered Hepatic Targeted Delivery. In: Henrik J. Ditzel et al. (eds.) Design and Delivery of siRNA Therapeutics, Methods in Molecular Biology. Springer, Singapore. 2021, 77-100.
9. Huang D, Huang Y, Li Z*. Chapter 11 - Transdermal Delivery of Nucleic Acid Mediated by Punching and Electroporation. In: Li S., Chang L., Teissie J. (eds) Electroporation Protocols. Methods in Molecular Biology. Humana, New York, 2020, 101-112.
10. Weng Y, Huang Y*. Chapter 7 - The Advances of Biomacromolecule-based Nanomedicine in Brain Disease. In: Xue X. (eds) Nanomedicine in Brain Diseases. Springer, Singapore. 2019, 181-208.
11. 黄渊余*,生命科学原理与技术学习指导和习题集. 北京：科学出版社.2022,第五章,32-51.ISBN: 978-7-03-071412-1
12. 黄渊余*,谭信.基因与遗传.马宏.生命科学原理与技术.北京：科学出版社.2019,第五章,97-140.(Huang Y*. Tan X. Chapter 5 - Gene and Genetics. In: Ma H. (eds) Principle and Technologies of Life Science. Science Press. 2020, 97-151)
9.3 授权和申请专利（不完全举例）：
1. 梁兴杰; 黄渊余;陆梅. siRNA输送载体及其制备方法和应用. 申请号: 202111240545.6.
Liang X.-J., Huang Y., Lu M. siRNA delivery carrier, and its preparation and use thereof. Application No: 202111240545.6 (CN).
2. 黄渊余,梁兴杰,陆梅. 特异性抑制PAK4基因表达的siRNA及其应用. 申请号: 202111242145.9.
Huang Y., Liang X.-J., Lu M. siRNAs targeting PAK4, and use thereof. Application No: 202111242145.9 (CN).
3. 黄渊余;郭帅. 可电离脂质纳米颗粒组合物、制备方法及应用.申请号：202110713233.6.
Huang Y, Guo S. Ionizable lipid nanoparticle composition, preparation method and use thereof. Application No: 202110713233.6 (CN).
4. 黄渊余;翁郁华;李春辉;杨同仁. 一种特异识别人PLK1位点的sgRNA、质粒、纳米复合物和应用. 申请号：202110699974.3.
Huang Y, Weng Y, Li C, Yang T. A group of PLK1-targeted sgRNAs, plasmids, nanocomplexes, and use thereof. Application No: 202110699974.3 (CN).
5. 黄渊余;张萌洁. 一种抗肿瘤的工程化外泌体、制备方法和应用. 申请号：2021106043119.9.
Huang Y, Zhang M. An engineered antitumor exosome, and its preparation and application. Application No: 2021106043119.9 (CN).
6. 黄渊余;黄金宇;胡泊. 化合物、脂质体及其用途. 申请号：PCT/CN2021/094937.
Huang Y, Huang J, Hu B. Lipids, lipid nanoparticles, and use thereof. Application No: PCT/CN2021/094937
7. 屈锋;黄渊余;杨歌. 一组2019-nCoV S1蛋白的ssDNA适配体、筛选方法及应用. 申请号：202110286076.5.
Qu F, Huang Y, Yang G. A group of ssDNA aptamers binding with S1 protein of 2019-nCoV, and its screening methods and application. Application No: 202110286076.5 (CN).
8. 黄渊余;黄金宇;胡泊. 抑制 BACE1 基因表达的 siRNA 修饰物及其应用.申请号：202110192420.4.
Huang Y, Huang J, Hu B. Chemically modified siRNA targeting BACE1, and use thereof. Application No: 202110192420.4 (CN).
9. 黄渊余;曹毅 等. 一种抑制caspase 1 基因表达的siRNA 分子及其应用. 申请号: 202010990803.1
Huang Y, Cao Y, et al. siRNAs targeting caspase 1, and use thereof. Application No: 202010990803.1 (CN).
10. 黄渊余;曹毅 等. 一种抑制NLRP3基因表达的siRNA分子及其应用. 申请号: 202010990805.0
Huang Y, Cao Y, et al. siRNAs targeting NLRP3, and use thereof. Application No: 202010990805.0 (CN).
11. 赵永祥;黄渊余;黄勇;钟莉娉;何坚. 银纳米靶向治疗肿瘤系统的制备与应用. 申请号: 202010351882 .1
Zhao Y, Huang Y, Huang Y, Zhong L, He J. Preparation and application of silver nano-targeted tumor therapy system. Application No: 202010351882 .1 (CN).
12. 张鸿雁;高山;黄渊余.一种小干扰核酸和药物组合物及其用途. 申请号：201510551827. 6. PCT/CN2016/097560；国际公布号：WO2017036398A1. 中国授权公告号: CN108431224B.
Zhang HY, Gao S, Huang Y. Small Interfering RNA, Pharmaceutical Composition, and Application Thereof. PCT/CN2016/097560, WO2017036398A1, CN108431224B.
13. 张鸿雁;高山;黄渊余. 一种siRNA、含有该siRNA的药物组合物和缀合物及它们的应用. 申请号：201510364229.8. PCT/CN2016/087034；国际公布号：WO2016206626A1. 日本授权号: JP6715325B2.
Zhang HY, Gao S, Huang Y. siRNA, Pharmaceutical Composition and Conjugate Which Contain siRNA, and Uses Thereof. PCT/CN2016/087034, WO2016206626A1, JP6715325B2.
14. 李志宏;梁子才;杜权;魏泽文;黄渊余. 一种用于向活体组织中的细胞内部输运核酸的柔性电极芯片. 申请号：201110150176.1；公告号：CN102367414B.
Li Z, Liang Z, Du Q, Wei Z, Huang Y. A flexible electrode chip for transporting nucleic acid into the interior of cells in living tissue. CN102367414B.
9.4 获奖与荣誉（2008年以后）
1. 2023年07月，获首都前沿学术成果（北京市科协）
2. 2022年08月，北京市科学技术奖自然科学一等奖（第九完成人）
3. 2022年09月，“师缘·北理”庆祝第38个教师节暨教师表彰大会优秀人才类表彰
4. 2022年04月，广西科学技术奖自然科学一等奖（第五完成人）
5. 2022年01月，国家高层次人才
6. 2021年11月，北京理工大学“十三五”科技工作先进个人
7. 2021年11月，ChinaNanomedicine 2021（第四届国际纳米药物大会），青年学者论坛优秀报告奖
8. 2020年08月，北京市“科技新星”
9. 2019年12月，北京市科协青年托举人才
10. 2019年08月，中美纳米医学与纳米生物技术学会“Rising Star”奖
11. 2017年05月，中国博士后科学基金会“全国百优博士后” 选介
12. 2016年12月，北京大学优秀博士后
13. 2015年04月，北京大学-清华大学生命科学联合中心优秀博士后基金获得者
14. 2013年07月，北京大学优秀博士学位论文
15. 2012年12月，北京大学“学术十杰”
16. 2012年12月，北京大学“创新奖”（学术类）
17. 2012年11月，教育部博士研究生国家奖学金
18. 2012年05月，北京大学分子医学研究所首届“顾吴”奖学金
19. 2011年12月，北京大学“创新奖”（学术类）
20. 2011年12月，北京大学“五四”奖学金
21. 2011年11月，教育部博士研究生学术新人奖
22. 2010年12月，北京大学“创新奖”（学术类）
2010年12月，北京大学“康宁”奖学金